UNSPSC 51282944: Sparfloxacin

This classification denotes a quinolone antibiotic and antitubercular agent with the molecular formula C19H22F2N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q90AGA787L, chemically known as 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, but generally known as sparfloxacin, which bears US NIH Compound Identifier 5257. European Medicines Agency schedules Sparfloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10610MIG.

UNSPSC 51282944 Sparfloxacin, a Commodity code, does not align with the state and local procurement opportunities recently tagged under it. The code nominally denotes a specific fluoroquinolone antibiotic; however, the recent solicitations posted under this code span naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, direct-to-manufacturer prescription programs, and medical and first aid supplies for emergency response. None of these opportunities explicitly reference sparfloxacin or narrow-spectrum antibiotic procurement. The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), a municipal fire department (City of Tampa), and a multistate cooperative purchasing alliance (MMCAP, administered by Minnesota). The code shows little relevant recent activity aligned to its stated pharmaceutical scope.

The geographic spread of these misaligned opportunities spans Florida, Texas, Minnesota, and Oregon, reflecting the jurisdictions participating in MMCAP and the individual state and local health and emergency-services procurement efforts. The only opportunity with a posted response date is the MMCAP RFP (due March 26, 2026), a multistate cooperative vehicle for generic pharmaceuticals and OTC products through authorized wholesalers. The City of Tampa's medical and first aid supplies IFB (due March 13, 2026) targets emergency response consumables, not pharmaceuticals. Seminole County's naloxone and drug deactivation systems IFB (due July 26, 2023) predates the current review period. The Texas HHS RFI (due April 3, 2026) explores direct-to-manufacturer prescription programs but does not specify sparfloxacin or any single-drug procurement. The code's tagging appears to reflect a data-classification error rather than genuine pharmaceutical product procurement aligned to sparfloxacin's therapeutic use.